SG Americas Securities LLC Increases Stock Holdings in Viridian Therapeutics, Inc. $VRDN

SG Americas Securities LLC lifted its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 81.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 60,044 shares of the company’s stock after buying an additional 26,956 shares during the quarter. SG Americas Securities LLC owned approximately 0.06% of Viridian Therapeutics worth $1,174,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in VRDN. Hudson Bay Capital Management LP increased its holdings in Viridian Therapeutics by 46.6% during the 3rd quarter. Hudson Bay Capital Management LP now owns 175,251 shares of the company’s stock valued at $3,782,000 after acquiring an additional 55,689 shares in the last quarter. Jennison Associates LLC purchased a new stake in shares of Viridian Therapeutics in the fourth quarter valued at about $35,915,000. Knott David M Jr lifted its holdings in shares of Viridian Therapeutics by 27.4% in the third quarter. Knott David M Jr now owns 116,574 shares of the company’s stock valued at $2,516,000 after purchasing an additional 25,091 shares in the last quarter. Perceptive Advisors LLC lifted its holdings in shares of Viridian Therapeutics by 108.1% in the fourth quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock valued at $94,689,000 after purchasing an additional 1,580,303 shares in the last quarter. Finally, Avoro Capital Advisors LLC acquired a new stake in shares of Viridian Therapeutics in the fourth quarter valued at approximately $46,680,000.

Insider Transactions at Viridian Therapeutics

In other news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the stock in a transaction on Monday, May 11th. The stock was purchased at an average cost of $17.00 per share, with a total value of $19,999,990.00. Following the purchase, the director owned 5,090,928 shares of the company’s stock, valued at approximately $86,545,776. The trade was a 30.05% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 2.40% of the company’s stock.

Viridian Therapeutics Price Performance

Viridian Therapeutics stock opened at $19.40 on Friday. Viridian Therapeutics, Inc. has a 12-month low of $13.18 and a 12-month high of $34.29. The stock has a market capitalization of $2.00 billion, a P/E ratio of -5.84 and a beta of 0.90. The firm’s 50-day moving average is $16.69 and its two-hundred day moving average is $23.80. The company has a debt-to-equity ratio of 0.10, a current ratio of 15.15 and a quick ratio of 15.15.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.16. The business had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.04 million. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. The company’s quarterly revenue was up 95.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.87) earnings per share. Equities analysts predict that Viridian Therapeutics, Inc. will post -3.87 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on VRDN. Weiss Ratings cut shares of Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Royal Bank Of Canada upped their target price on Viridian Therapeutics from $34.00 to $35.00 and gave the company an “outperform” rating in a research note on Tuesday. HC Wainwright lowered their target price on Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Needham & Company LLC reissued a “buy” rating and set a $32.00 price target on shares of Viridian Therapeutics in a research report on Monday, June 29th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $39.00 price target on shares of Viridian Therapeutics in a research report on Tuesday. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.79.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.